Podcast: Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
Sets Sail On Own Post Bayer, Merck, Lantheus Partnerships
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
